论文部分内容阅读
目的探讨3种抗菌药物治疗急性支气管炎的药物经济学情况。方法入选病例120例,按就诊顺序分为A、B、C组各40例,运用药物经济学成本-效果分析法对莫西沙星片(A组)、阿奇霉素片(B组)、头孢克洛胶囊(C组)进行对比分析评价。结果 3组药物治疗方案总成本分别为19 263.20,18 690.80,19 266.80元;有效率分别为97.50%,77.50%,70.00%,差异有统计学意义(P<0.05);成本-效果比分别为197.57,241.17,275.24。结论成本-效果显示莫西沙星为急性支气管炎治疗最佳方案。
Objective To investigate the drug economics of three kinds of antimicrobial agents for the treatment of acute bronchitis. Methods A total of 120 cases were enrolled in this study. According to the order of treatment, 40 cases were divided into groups A, B and C respectively. The effects of moxifloxacin tablets (group A), azithromycin tablets (group B) and cefaclor Capsule (C group) comparative analysis of evaluation. Results The total cost of the three groups was 19 263.20, 18 690.80 and 19 266.80 respectively. The effective rates were 97.50%, 77.50% and 70.00%, respectively, with significant differences (P <0.05). The cost-effectiveness ratios were 197.57, 241.17, 275.24. Conclusion Cost-effectiveness shows that moxifloxacin is the best treatment for acute bronchitis.